The CPH circus looks to be leaving town after Canadian listed PharmaCielo (PCLO.V) made an all-scrip AUD $122M offer to acquire Creso Pharma (CPH.ASX), which
A late Fumble today folks – been one of those weeks where no matter how much I flooded my body with Berocca it just wouldn’t
The footy season has wrapped up in Oz and things ended the way they should according to the laws of the Animal Kingdom. The Eagles
We’re back with the fumble. Last week I was indisposed, apologies. A sexy nurse was slicing open my right arm and stuffing a camera through
Muay Thai is the national sport here in my adopted homeland. Known as ‘the science of eight limbs‘ it’s a brutal contest – a knee
I still remember what it felt like to wake up and realize it was Friday when I was entombed in a corporate cubicle. Everything was
It’s been a long ten months for CannPal Animal Therapeutics (CP1.ASX) shareholders having watched their investment hover around the $0.20 IPO issue price. While other
On the surface, the rights issue announced by Creso Pharma (CPH.ASX) looks to be a decent deal for long-suffering shareholders, albeit it a little unusual.
The Australian government has really dropped the ball when it comes to easy access to medicinal cannabis. Want proof? Sometimes all you need is a
So Auscann (AC8.ASX) has finally released the details of their share purchase plan (SPP) and retail have been shafted, yet again. Here are the main
AusCann (AC8.ASX) shares were placed in a trading halt Tuesday July 3, 2018 as the AFR Street Talk column reported the company was seeking to
A quick Wednesday update covering Telstra (TLS.ASX), Optus, capital raisings undertaken by Roto-Gro International (RGI.ASX) and Botanix Pharmaceuticals (BOT.ASX) and, last but not least, Crown
The slightest of oil bumps got the Canadian mid-caps spending like drunken sailors, the market hates it. Meanwhile, mining deals are so cheap that flush
After being cold carded for months now, the weed posse ain’t happy, and a few are asking what they should do? They want to know
Contrarians are a funny bunch. When it’s raining they play outside. In the winter they eat ice-cream, in the summer they slurp soup. Preferred holiday
Deutsche Bank and citi implicated in Oz banking scam, and a curious Canopy Growth disclosure has the Datajam looking in its crystal ball. Here’s what
Looks like it might be a grim Easter for Angel Seafood Holdings Ltd (AS1.ASX) shareholders after a lackluster IPO has seen the price tank 30%
Anyone who has followed the Creso Pharma (CPH.ASX) story over the past year was aghast when they read the recent company announcement revealing that CPH
So there I was minding my own business in a makeshift bar along Sukhumvit Road, observing the ladyboys fight the police when I was rudely
While the first snow recently dusted the streets of Vancouver, Sydneysiders have sweltered with temperatures soaring past 43 degrees Celcius (109°F) this past weekend. The
Something quite remarkable took place at the 2002 Winter Olympics in Salt Lake City. Australian Steven Bradbury took out the gold medal in the men’s
The Hydroponics Company (THC.ASX), which listed on 4th May, is the latest cannabis outfit to tap the market for funds, halting their stock through the
We’ve handed out plenty of bouquets to Creso Pharma (CPH.ASX) since initiating coverage – time for a brickbat. That’s how we roll here at Equity
Stocks are a little like children. You have your favourites and when they venture out into the world and do well it’s hard not to
Melbourne Cup day is one of the few things I miss about not being in Australia. Last week the race that stops a nation was
Telstra (TLS.AX), Australia’s largest retail telecommunications provider, finds itself at a crossroads in a rapidly changing digital landscape.
Its customer service is woeful at best and its only real point of differentiation in the market has been network coverage. Unable to exploit the monopoly that powered earnings until the mid-2000s, they are now faced with credible competition.
UPDATE: Less than 12 hours after going to press CBA announces Narevs’ departure from the bank in 2018. Welcome to the 2nd week on The
